Samchundang Pharm FY 2025 Annual ReportBeta
Samchundang Pharm annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 20, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Samchundang Pharm FY 2025 Annual Report Analysis
Business Overview
- • Core business model: prescription pharmaceutical manufacturing and sales, with ophthalmic products comprising 61.06% of sales in FY2025
- • Aflibercept biosimilar (SCD411) reached major regulatory approvals in Japan (Sep 2025), Canada (Jun 2025), and Europe (Aug 2025) with multiple exclusive sales contracts
Management Discussion & Analysis
- • Revenue KRW 231.8B (+9.9% YoY); operating profit KRW 846.7M (+220.5% YoY); net income KRW 1.2B (+336.9% YoY)
- • Ophthalmology segment 61.1% of sales; overseas Aillia biosimilar (SCD411) sales in Canada drove profit increase
Risk Factors
- • KRW 4.61B pre-tax profit sensitivity for 10% USD/EUR/JPY/CAD/GBP exchange rate move, up from KRW 3.16B prior year
- • KRW 118.7B financial liabilities due within 1 year, up from KRW 70.3B prior year
Samchundang Pharm FY 2025 Key Financial MetricsDART
Total Assets
KRW 561.2B
▲ +8.0% YoY
Operating Cash Flow
KRW 9.8B
▼ -55.0% YoY
CapEx
KRW 46.1B
▲ +171.1% YoY
Source: KIFRS consolidated financial data from Samchundang Pharm annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding